22 results
8-K
LYEL
Lyell Immunopharma, Inc.
6 Jun 23
Departure of Directors or Certain Officers
4:02pm
and the date on which the Company terminates the engagement for cause pursuant to the Separation Agreement (such earlier date, the “End Date”). Pursuant
8-K
jrvzy 3mt
16 Dec 22
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
4:02pm
8-K
EX-10.1
xyiojfhrd
16 Dec 22
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
4:02pm
S-3ASR
EX-1.2
0iioyi
4 Aug 22
Automatic shelf registration
5:29pm
DEF 14A
5q7n0s3o
28 Apr 22
Definitive proxy
4:11pm
S-8
EX-4.2
23o31c dt
21 Jun 21
Registration of securities for employees
5:08pm
424B4
zpczv6kmzt42l9y6ib
18 Jun 21
Prospectus supplement with pricing info
12:00am
S-1/A
gbptgq2axx0q6
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
EX-3.4
kau ld0z9s7ncnw739
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
EX-10.15
43vm7sj6e umqqj0
9 Jun 21
IPO registration (amended)
7:12am
S-1
EX-10.15
3zd5ca
25 May 21
IPO registration
5:28pm
S-1
vm23fn5wacaciy3tlcm7
25 May 21
IPO registration
5:28pm
S-1
EX-10.9
i3euu sgoouoq9y2lzb
25 May 21
IPO registration
5:28pm
DRS/A
v2atv3oyrn2iqnh3
12 May 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.9
pfr06x fz9d0
12 May 21
Draft registration statement (amended)
12:00am